New stock news | Hanfang Pharmaceuticals submits application to Hong Kong Stock Exchange

According to the disclosure by the Hong Kong Stock Exchange on February 25, Shandong Hanfang Pharmaceutical Co., Ltd. (referred to as Hanfang Pharmaceutical) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with Zhongtai International as its exclusive sponsor. The prospectus shows that Hanfang Pharmaceutical is a comprehensive pharmaceutical company engaged in the production, sales and research and development of traditional Chinese medicine products. The company focuses on the treatment of skin and mucosal diseases, and excels in integrating traditional Chinese medical wisdom with modern medical science. According to data from Frost & Sullivan, based on sales revenue projections for 2024, Compound Huangbai Liquid Preparation ranks fourth in China's topical over-the-counter pharmaceutical market, with a market share of 1.1%.